Slide 1: FDA Approval of BRINSUPRI for Patients with Non-Cystic Fibrosis Bronchiectasis
August 12, 2025 FDA Approval of BRINSUPRI™ for Patients with Non-Cystic Fibrosis Bronchiectasis FDA: Food & Drug Administration
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a
Slide 3: Agenda and Speakers
Opening Remarks Label Details Closing Remarks Q&A Session 5-6 8 9 10 Slides Will Lewis Chair & CEO Agenda Speakers Dr. Martina Flammer Chief Medical Officer
Slide 4: Opening Remarks
Opening Remarks Will Lewis | Chair & CEO
Slide 5: A Historic Day for Patients with Bronchiectasis
A Historic Day for Patients with Bronchiectasis Bronchiectasis / NCFB refers to patients with non-cystic fibrosis bronchiectasis BRINSUPRI approved for adults & adolescents 12+ years diagnosed with NCFB Second time launching a first-in-disease therapy for patients in the U.S. Salesforce expected to
Slide 6: Frictionless Launch: Prioritizing Patient Access
Frictionless Launch: Prioritizing Patient Access 1 In the U.S., Europe, UK, and Japan only | NCFB: non-cystic fibrosis bronchiectasis | #: number Rebating expected to ensure favorable patient access $ annual U.S. list price met by a receptive payor audience ~25% to 35% Gross-to-net assumption >$5B P
Slide 7: Label Details
Label Details Dr. Martina Flammer | Chief Medical Officer
Slide 8: Label Offers Physicians Flexibility to Prescribe Either Dose of BRINSUPRI
Label Offers Physicians Flexibility to Prescribe Either Dose of BRINSUPRI to Patients NCFB: non-cystic fibrosis bronchiectasis | FEV1: forced expiratory volume in 1 second, a key measure of lung function| mg: milligram Approved in 10 mg and 25 mg tablet form for adults and adolescents 12+ years with
Slide 9: Closing Remarks
Closing Remarks A Historic Day for Patients: BRINSUPRI approval presents opportunity to potentially serve ~500K NCFB patients in the U.S. BRINSUPRI availability in the U.S. is expected to increase NCFB diagnoses and documented pulmonary exacerbations over time We are well-resourced and ready to deli
Slide 10: Q&A Session
Q&A Session Will Lewis Chair & CEO Sara Bonstein Chief Financial Officer Dr. Martina Flammer Chief Medical Officer Thank you to the patients, investigators, and employees who contributed to this approval!
Slide 11: Count us in.